Simplex Trading
DSGN icon

Simplex Trading’s Design Therapeutics DSGN Stock Holding History

Simplex Trading’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.68K Buy
+600
New +$7.48K ﹤0.01% 7796
2025
Q2 		– Sell
-1,500
Closed -$5K – 8881
2025
Q1 		$5K Buy
+1,500
New +$7.16K ﹤0.01% 7534
2024
Q4 		– Sell
-16,100
Closed -$86K – 8738
2024
Q3 		$86K Buy
+16,100
New +$75.7K ﹤0.01% 5386
2024
Q2 		– Sell
-2,600
Closed -$10K – 8985
2024
Q1 		$10K Sell
2,600
-100
-4% -$267 ﹤0.01% 7588
2023
Q4 		$7K Buy
2,700
+2,000
+286% +$4.58K ﹤0.01% 7645
2023
Q3 		$1K Buy
700
+200
+40% +$933 ﹤0.01% 8281
2023
Q2 		$3K Buy
+500
New +$3.06K ﹤0.01% 8207
2022
Q4 		– Sell
-100
Closed -$1K – 9427
2022
Q3 		$1K Buy
+100
New +$1.99K ﹤0.01% 9513

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Simplex Trading's DSGN Position: Q2 2026 in Review

Simplex Trading opened a new position in Design Therapeutics (DSGN) in Q2 2026: 172 shares worth $2.49K. The stake represents ﹤0.01% of the portfolio and ranks #8553 among its holdings. This is a return to the name: Simplex Trading previously reported a position in DSGN as recently as Q1 2025.

Simplex Trading first reported a position in DSGN in Q1 2023 and has held it in 10 quarters since. The position peaked at $40K in Q3 2024. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Simplex Trading held 172 shares of Design Therapeutics worth $2.49K as of Q2 2026.
  • Design Therapeutics was a new Simplex Trading position in Q2 2026.
  • Design Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #8553 holding.
  • Simplex Trading first reported a position in Design Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Simplex Trading's Design Therapeutics position peaked at $40K in Q3 2024.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.